Tumor markers in the management of patients with ovarian cancer.
Tuxen
M K
MK
Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.
Sölétormos
G
G
Dombernowsky
P
P
D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis; D018394:CA-125 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D037181:Lectins, C-Type; D008403:Mass Screening / Q000379:methods; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D010455:Peptides / Q000032:analysis; D011379:Prognosis; D012680:Sensitivity and Specificity; D019396:Tissue Polypeptide Antigen; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000032:analysis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001798:Blood Proteins; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D037181:Lectins, C-Type; D010455:Peptides; D019396:Tissue Polypeptide Antigen; C048648:tetranectin; D014359:Trypsin Inhibitor, Kazal Pancreatic